Welcome to our dedicated page for Sage Therapeutic news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutic stock.
Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical leader pioneering treatments for central nervous system disorders, including depression and rare neurological conditions. This page provides investors and researchers with a comprehensive repository of official company updates and third-party analysis.
Access timely announcements on clinical trial milestones, regulatory developments, and strategic collaborations shaping the future of neuroscience therapeutics. Our curated feed includes earnings reports, research publications, and partnership disclosures critical for evaluating SAGE’s progress in addressing unmet medical needs.
Key content focuses on GABA/NMDA receptor-targeted therapies, pipeline advancements for postpartum depression treatments, and epilepsy-related innovations. Bookmark this page to monitor how Sage Therapeutics’ scientific expertise translates into potential market opportunities within the competitive CNS pharmaceutical landscape.
Sage Therapeutics reported strong Q1 2025 financial results, with ZURZUVAE generating $13.8 million in collaboration revenue, marking a 21% increase from Q4. The company achieved over 3,000 shipments for women with postpartum depression (PPD), up 22% from the previous quarter.
Key highlights:
- Cash position of $424 million as of March 31, 2025
- Cash runway expected to support operations until mid-2027
- OBGYNs account for 80% of all prescriptions
- 70% of ZURZUVAE prescriptions are first-time PPD treatments
The company's R&D expenses decreased to $22.8 million from $71.7 million year-over-year, while SG&A expenses increased to $57.6 million from $52.6 million. Net loss improved to $62.2 million compared to $108.5 million in the same period last year. Sage continues its strategic alternatives review process and expects data from SAGE-319's Phase 1 study by late 2025.
Sage Therapeutics (NASDAQ: SAGE) has scheduled its first quarter 2025 financial results announcement and business updates for Tuesday, April 29, 2025, at 4:30 p.m. ET. The company will host a live webcast accessible through their investor relations website at investor.sagerx.com. The webcast recording will remain available for up to 30 days after the event.
Sage Therapeutics (SAGE) announced a leadership transition as Chief Medical Officer Dr. Laura Gault will depart the company effective March 21, 2025. Dr. Gault, who joined in November 2022, has been responsible for leading the company's product pipeline development across all stages.
Chief Scientific Officer Mike Quirk will temporarily assume key responsibilities, including providing strategic guidance for clinical development programs. The company acknowledged Dr. Gault's contributions, particularly highlighting her advocacy for maternal mental health advancement.
Sage Therapeutics (SAGE) reported its Q4 and full-year 2024 financial results, highlighting strong growth in its postpartum depression treatment ZURZUVAE. The company achieved nearly 2,500 shipments in Q4 2024, a 21% increase from Q3, with over 6,600 prescriptions delivered throughout 2024.
Q4 ZURZUVAE collaboration revenue was $11.4 million, with full-year revenue reaching $36.1 million. The company maintains a strong financial position with $504 million in cash and equivalents, expecting runway through mid-2027. Greater than 95% of Commercial and Medicaid lives are covered, with OBGYNs accounting for almost 80% of prescriptions.
Net loss for Q4 2024 was $95.8 million, compared to $32.7 million in Q4 2023. Full-year 2024 net loss was $400.7 million. The company expects overall operating expenses to decrease in 2025, reflecting R&D reductions and cost savings from the October 2024 reorganization.
Sage Therapeutics (NASDAQ: SAGE) has announced it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET. During the webcast, the company will review its fourth quarter and full year 2024 financial results and provide recent business updates. Investors can access the webcast through the company's investor relations website at investor.sagerx.com. A replay will be available after the event and archived for up to 30 days.
Sage Therapeutics (NASDAQ: SAGE) has announced that its Board of Directors has initiated a process to explore strategic alternatives, including potential strategic transactions, business combinations, or sale. The Board has unanimously rejected an unsolicited, nonbinding proposal from Biogen (NASDAQ: BIIB) to acquire all outstanding shares not already owned by Biogen for $7.22 per share, received on January 10, 2025.
The Board concluded that Biogen's proposal significantly undervalues Sage and is not in shareholders' best interests. While conducting the strategic review, Sage remains focused on establishing ZURZUVAE as the standard of care for women with postpartum depression (PPD). The company has not set a timetable for the review process and has not made any decisions regarding potential strategic alternatives.
Sage Therapeutics (SAGE) has announced its 2025 strategic focus at the J.P. Morgan Healthcare Conference, highlighting plans for ZURZUVAE, the first once-daily 14-day oral treatment for postpartum depression (PPD). The company aims to establish ZURZUVAE as the first-line therapy for PPD through increased commercial investments, including sales force expansion and digital marketing campaigns.
Key financial highlights include substantial expected decreases in R&D and G&A expenses in 2025, with an extended cash runway to mid-2027. The company's pipeline prioritization focuses on SAGE-319, currently in Phase 1 trials for neurodevelopmental disorders, with data expected by late 2025. Additionally, Sage is evaluating SAGE-324 for potential indications including seizures in developmental and epileptic encephalopathies, with an update expected mid-2025.
The company anticipates that existing cash, cash equivalents, and marketable securities, along with collaboration funding and estimated revenues, will support operations through mid-2027, despite increased ZURZUVAE commercialization investments with Biogen in 2025.
Sage Therapeutics (SAGE) has received an unsolicited, nonbinding acquisition proposal from Biogen (BIIB) to purchase all outstanding shares not already owned by Biogen at $7.22 per share. The Sage Board of Directors, along with independent financial and legal advisors, will review and evaluate the proposal to determine the best course of action for the company and its shareholders. The company emphasized that there is no guarantee of a transaction resulting from this proposal, and shareholders are not required to take any action at this time.
Sage Therapeutics (NASDAQ: SAGE) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA.
Investors and interested parties can access a live webcast of the presentation through the Investor page on Sage's website at investor.sagerx.com. The presentation recording will be available for replay and archived for up to 30 days following the event.
Sage Therapeutics (NASDAQ: SAGE) has announced its upcoming participation in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference. The event is scheduled for Wednesday, December 4, 2024, at 9:00 a.m. ET in New York, NY. Interested parties can access a live webcast of the presentation through the Investor page on Sage's website at investor.sagerx.com. The presentation recording will remain available for up to 30 days following the event.
FAQ
What is the current stock price of Sage Therapeutic (SAGE)?
What is the market cap of Sage Therapeutic (SAGE)?
